Date: 2012-01-24
Type of information: R&D agreement
Compound: mdm2/p53 inhibitors
Company: Boehringer Ingelheim (Germany) Priaxon (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: The role of the human p53 tumor suppressor protein in controlling the cell cycle and monitoring the integrity of the genome has made it known as the "guardian of the genome". Besides the functional loss of p53 through mutation, it can also be inactivated by the overexpression or amplification of MDM2 (murine double minute 2), which is the case in many p53 wild-type tumors. Thus, disruption of the MDM2-p53 interaction is considered a novel therapeutic strategy for cancer cells that still are endowed with wild-type p53, and a variety of small molecule drug like compounds have been reported that bind to the p53 binding site of MDM2.
Disease: cancer
Details: Boehringer Ingelheim and Priaxon, will prolongate their research and development collaboration on mdm2/p53 inhibitors for the treatment of cancer.The companies will continue working jointly to identify and advance drug candidates into pre-clinical development. Thereafter, Boehringer Ingelheim will drive the development and commercialisation of the potential cancer treatments arising from the collaboration. Priaxon has already developed promising mdm2/p53 inhibitors with its PriaXplore® technology.
Financial terms: Priaxon is entitled to up to €86 million in milestone payments upon achievement of certain development, regulatory and commercial milestones as well as royalties on potential future net sales of products.
Latest news:
